Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2009

View Archived Issues

Ex vivo IL-10 gene therapy correlates with functional repair of lung transplants

CH-5137291evaluated in preclinical models of castration-resistant prostate cancer

E-3810 exhibits potent antiangiogenic activity in preclinical studies

Favorable safety and lipid profiles with anacetrapib therapy in hyperlipidemia

Pioglitazone slows atherosclerosis progression in type 2 diabetes patients

Vasopressin V1a and V1b receptor antagonists reported by sanofi-aventis

Schering-Plough claims A2A receptor antagonists for the treatment of PD

Novel histamine receptor modulators in early development at Medivation

5-HT, DA and NE reuptake inhibitors disclosed by GSK for the treatment of anxiety

Vertex is developing ABC transporter modulators for the treatment of cystic fibrosis

Advanced BioHealing initiates prospective clinical trial for venous leg ulcers

Alkermes initiates phase II trial of ALKS-33 for alcohol dependence

Anacor starts phase I trial of AN-3365 for Gram-negative infections

Albireo presents clinical data on A-3309 in chronic idiopathic constipation

Pluristem Therapeutics reports 3-month follow-up data for PLX-PAD

Vivus reports results from phase III avanafil study in erectile dysfunction

Genzyme reports results from phase II/III trial of GENZ-644470 in hyperphosphatemia

Asterand to acquire BioSeek

Biocompatibles acquires Astron Clinica's inventory and intellectual property assets

FDA issues complete response to Genentech and Biogen's applications for rituximab in CLL

FDA committee votes that data for Prevnar 13 vaccine support safety and effectiveness

Sangamo presents update on phase I safety study of SB-728-T for HIV/AIDS

Chugai files for additional indication for Epogin in Japan

deCODE genetics files for bankruptcy in the U.S.

ImmuPharma reports final results from phase IIb trial of Lupuzor in SLE

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...